Regulatory Harmony Needed To Fulfill Personalized Medicine Promise
This article was originally published in The Gray Sheet
Executive Summary
Barriers to reaching the full potential of personalized medicine diagnostics include low reimbursements, best methods to validate tests and physician education needs, as well as discordance between regulations for lab-developed tests and diagnostic test kits, witnesses told a House panel July 23.
You may also be interested in...
Senators Push OMB For Lab-Developed Test Guidance, Academic Labs Resist
Several Democratic Senators want the Office of Management and Budget to release the FDA draft guidance on lab-developed tests that has been stuck at OMB for years. Academic clinical labs send their own letter to the budget office, pleading that the guidance not be released.
Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law
Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.